A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants

Study Identifier:
ALXN1720-HV-103
ClinicalTrials.gov Identifier:
NCT06208488
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Gefurulimab PFS-SD
  • Drug: Gefurulimab AI
Date
Nov 2023 - Sep 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 65 Years
Requirements Information
Sex
Female & Male
Age
18 - 65 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Gefurulimab PFS-SD
  • Drug: Gefurulimab AI
Date
Nov 2023 - Sep 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 65 Years years
Requirements Information

Protocol Summary

This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, immunogenicity, and device performance of gefurulimab.

Trial Locations

Location
Status
Location
Research Site
Toronto, Ontario, Canada, M9L 3A2
Status
N/A
Location
Research Site
Laval, Quebec, Canada, h7v 4bc
Status
N/A